Symphogen And Meiji Seika Kaisha Ltd. Achieve Milestone In Discovery Collaboration For Recombinant Polyclonal Antibody, Sym006

Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the discovery, development and commercialization of a recombinant polyclonal antibody therapeutic, Sym006, that targets an undisclosed bacterial pathogen. The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development. As a result, Symphogen will receive a milestone payment from Meiji under the terms of the agreement.

More: continued here

Filed under: Immune System / Vaccines on December 5th, 2008